C4X Discovery Holdings plc (LON:C4XD)

C4X Discovery Holdings plc (LON:C4XD)

Share Price
49.50 p
0 (0.00 %)
Market Cap
£28.61 m
Proactive Investors - Run By Investors For Investors

C4X Discovery Holdings plc

C4X Discovery aims to become the world's most productive drug discovery engine by exploiting cutting edge technologies to design and create best-in-class small-molecule candidates targeting a range of high value therapeutic areas. The company's goal is to drive returns through early-stage revenue-generating deals with the pharmaceutical industry.

Market: AIM:C4XD
52-week High/Low: 114.956p / 33.250p
Sector: Health Care, Equipment & Services
Market Cap: £28.61 m
Website: www.c4xdiscovery.com
col 3
col 4
col 5
col 6

Big Picture – A Deep Dive Examination of C4X Discovery Holdings plc

C4X Discovery Holdings plc Snapshot

C4X Discovery has a state-of-the-art suite of proprietary technologies across the drug discovery process. The company's innovative DNA-based target identification platform (Taxonomy3®) utilises human genetic datasets to identify novel patient-specific targets leading to greater discovery productivity and increased probability of clinical success. This is complemented by C4XD's novel drug design platform which comprises two innovative chemistry technologies, Conformetrix and Molplex, that combine 4D molecular shape analyses (based on experimental data) with best-in-class computational chemistry. This provides new and unprecedented insight into the behaviour of drug molecules, enabling the production of potent selective compounds faster and more cost effectively than the industry standard.

C4X Discovery is advancing its in-house pipeline that is primarily focused on the high value therapeutic areas of inflammation, neurology and cancer (including immuno-oncology) with a number of new drug candidates identified and further progress made towards the pre-clinical licensing discussions. In selecting new targets and executing new drug discovery programmes, C4X Discovery focuses on high-value disease areas that are the subject of significant licensing activity and will continue to also maximise value from opportunistic areas such as addiction and diabetes. The Company recently signed a licensing agreement with Indivior for a pre-clinical addiction programme worth up to $294 million.

The Company was founded as a spin-out from the University of Manchester. It has a highly experienced management team and Board who have delivered significant value creation within the healthcare sector historically and have enabled C4XD to reach multiple value inflexion points since IPO.

c4xd about moleule with vr


Highly Valuable Markets

C4X Discovery is using its unique proprietary technologies to build a pipeline of high quality small molecule drug candidates addressing valuable markets with high unmet medical need.

c4x pipeline 2019

C4X Discovery continues to advance its in-house pipeline that is primarily focussed on the high value therapeutic areas of immunology/inflammation, neurology/neurodegeneration and cancer (including immuno-oncology) as these areas are subject to the most significant R&D licensing activity in the pharmaceutical sector (BIO Industry Analysis, “Emerging, Therapeutic Company Investment and Deal Trends”, May 2018).

1. 4 additional early discovery programmes currently paused due to insufficient chemical opportunity

2. Disease targets with high commercial opportunity and partnering potential against which C4X’s proprietary drug discovery technologies can provide a competitive advantage in development.

Underpinning the world's most productive drug discovery engine

C4X Discovery aims to become the world’s most productive drug discovery and development company by exploiting cutting-edge technologies to design and create best-in-class drug candidates.

C4X Drug Discovery Engine

The Company has a unique software platform for determining the flexible 3D shapes of drug molecules from experimental in vitro data and this enables the rapid design and discovery of novel and potent drugs for diseases with high unmet medical need across broad therapeutic areas.

Targets are selected through traditional industry methods and C4X Discovery’s proprietary Taxonomy3® platform, which enables the discovery of targets that cause disease, rather than those that are simply associated with its symptoms. This provides the best starting point for drug discovery, biomarker identification and patient stratification, and significantly improves the chances of clinical success. The measurement, analysis and use of dynamic 3D-shapes is at the heart of C4XD's drug discovery engine. The focus and clarity that these data provide allows the Company to make rapid progress in developing new and better drugs at a fraction of the cost, compared to best industry practice.


United Kingdom.

The C4X Discovery management team has significant drug discovery and development expertise and experience, with a track record of value creation.

Clive Dix, PhD
Chief Executive Officer (Director)

  • Serially successful biotech entrepreneur
  • Exits include Convergence Pharmaceuticals (2015) and PowderMed Ltd (2006)
  • Ex UK Research Director, GlaxoWellcome
  • Former BIA Chairman

Craig Fox, PhD
Chief Scientific Officer (Director)

  • More than 20 years’ drug discovery experience from target selection to Phase 2 clinical studies
  • Previously Director of Respiratory Research at Pulmagen Therapeutics, Argenta
  • Managed several collaborations and partnerships at Pulmagen, including those with AstraZeneca, Chiesi, Domantis, Dr Reddy’s, SkyePharma and Teijin Pharma
  • Ex Bayer Pharmaceuticals

Brad Hoy
Chief Financial Officer (Director)

  • More than 20 years’ experience in the pharmaceutical and biotechnology industries
  • Previously Chief Financial Officer of Plethora Solutions Holdings plc, Chief Executive Officer of Xcellsyz Limited, and Senior Director of Geron Corporation’s stem-cell focused UK subsidiary
  • Co-founder of Seven Hills Venture Partners and previously served on the Board of Directors for e-Therapeutics plc for nine years.

Bhavna Hunjan
Head of Corporate Strategy and Development

  • 10 years’ experience across investment banking and strategic consultancy, providing commercial advice including business strategy, deal structuring and execution, product positioning, portfolio reviews, and regulatory change
  • Previously Senior Strategist at Cancer Research UK
  • Ex Lehman Brothers, Nomura International plc, and PricewaterhouseCoopers


Shareholder Information

Significant Shareholders

In so far as the company has been notified, the following table represents significant shareholders as at March 7th 2019;

Name Number of shares held Percentage of issued share capital
Aquarius Equity Partners (Manchester) 7,459,425 12.9%
Polar Capital (London) 5,555,555 9.6%
Canaccord Genuity Wealth Mgt (London) 5,216,924 9.0%
Calculus Capital (London) 4,609,889 8.0%
Baillie Gifford & Co (Edinburgh) 3,694,172 6.4%
Legal & General Investment Mgt (London) 3,552,000 6.1%
Mr Charles D Blundell (UK) 3,035,000 5.3%
Mr Andrew Almond (Regional (England)) 3,010,000 5.2%
Mr Andrew W Black (UK) 2,845,098 4.9%

AIM securities in issue: 57,792,636 (no shares held in Treasury)

The percentage of AIM securities not in public hands is 24.2%

Directors and their interests

Name Number of shares held Percentage of issued share capital
Clive James Dix 1,414,936 2.4%
Alexander James Stevenson 485,403 0.8%
Harry Finch 321,425 0.6%
Craig Fox 7,183 <0.1%


Address - Main Office

C4X Discovery Holdings PLC
Manchester One
53 Portland Street
M1 3LD

United Kingdom


[email protected]


+44 (0)161 235 5085

Address - London Office

Euston House
4th Floor
24 Eversholt Street

Nominated Advisor and Broker

Panmure Gordon (UK) Limited (NOMAD)

One New Change, London EC4M 9AF

Telephone: +44 (0)20 7886 2500


Auditors and Tax Advisors


1 The Embankment, Neville Street, Leeds LS1 4DW

Telephone: +44 (0)113 231 3000




Capita Registrars Ltd

The Registry, 34 Beckenham Road, Beckenham, Kent BR3 4TU

Telephone: 0871 664 0300*, Overseas: +44 (0) 20 8639 3399

*Calls to 0871 numbers are charged at 10 pence per minute plus network extras. Lines are open from 8:30am to 5:30pm UK time, Monday to Friday.


Legal Advisors

Schofield Sweeney LLP

Springfield House, 76 Wellington Street, Leeds LS1 2AY

Telephone: +44 (0)1132 206270



Financial PR


41 Lothbury, London, EC2R 7HG

Telephone: +44 (0)20 3709 5700


Address - Main Officemanchester one c4xd offices

C4X Discovery Holdings PLC
Manchester One
53 Portland Street
M1 3LD

United Kingdom


[email protected]


+44 (0)161 235 5085

Address - London Office

Euston House
4th Floor
24 Eversholt Street



Columns Including C4XD


Market Reports Including C4XD

Video RSS



© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use